Recently, it was demonstrated that lineage-committed oligodendrocyte precursor cells (OPCs) can be converted to multipotent neural stem-like cells, capable of generating both neurons and glia after exposure to bone morphogenetic proteins. In an effort to understand and control the developmental plasticity of OPCs, we developed a high-throughput screen to identify novel chemical inducers of OPC reprogramming. Using this system, we discovered that inhibition of histone deacetylase (HDAC) activity in OPCs acts as a priming event in the induction of developmental plasticity, thereby expanding the differentiation potential to include the neuronal lineage. This conversion was found to be mediated, in part, through reactivation of sox2 and was highly reproducible at the clonal level. Further, genome-wide expression analysis demonstrated that HDAC inhibitor treatment activated sox2 and 12 other genes that identify or maintain the neural stem cell state while simultaneously silencing a large group of oligodendrocyte lineage-specific genes. This series of experiments demonstrates that global histone acetylation, induced by HDAC inhibition, can partially reverse the lineage restriction of OPCs, thereby inducing developmental plasticity.
D
uring mammalian development, stem cells become progressively restricted in the tissue types to which they can give rise, eventually differentiating into a single cell type. Classically, this process was considered irreversible. However, recent evidence suggests that differentiated cells can gain plasticity when transplanted into an embryonic environment (1) or, more strikingly, when a cell is forced to express unique gene combinations (2) (3) (4) . Furthermore, in rare instances, progenitor cells can be induced by small molecules or growth factors to give rise to, what would otherwise be, restricted lineages (5, 6) .
In the developing central nervous system, oligodendrocyte precursor cells arise from multipotent neural stem cells (NSCs) before they terminally differentiate into oligodendrocytes (OLs) (7) . In vitro, oligodendrocyte precursor cells (OPCs) were believed to exist as bipotent and highly proliferative glial progenitor cells that can give rise to both OLs and type 2 astrocytes but were restricted from differentiating into neurons (8, 9) . However, it was recently demonstrated that OPCs may have a wider developmental potential and can be converted to multipotent neural stem-like cells, capable of generating both neurons and glial cells after exposure to bone morphogenetic proteins (BMPs) (6) . Analysis of this increase in developmental potential revealed transcriptional activation of NSC genes and silencing of OL lineage-specific genes that involved epigenetic modifications on histones (i.e., acetylation and methylation) and chromatin remodeling (10) .
Clearly, there is considerable interest in understanding, as well as ultimately controlling, these complex processes for regenerative therapies. In particular, the identification of small molecules that induce reprogramming of mammalian cells would provide further insights into the mechanisms that control cellular plasticity and may ultimately provide chemical reagents that make it possible to use healthy, abundant, and easily accessible adult cells to generate different types of stem/progenitor cells for therapeutic applications. Here, we identify a class of small molecules, histone deacetylase (HDAC) inhibitors, that, when used in conjunction with basic fibroblast growth factor (bFGF), are capable of reprogramming OPCs to a state of multipotency by global histone acetylation.
Results
High-Throughput Chemical Screening Strategy. To develop a high throughput screen to identify novel chemical inducers of OPC reprogramming ( Fig. 1A) , purified primary rat OPCs were transfected with a reporter construct that uses a 5.5-kb region of the sox2 promoter to drive eGFP expression (P/Sox2-eGFP; Fig.  1 A) (11) . The SRY-related, HMG-box containing transcription factor Sox2 is expressed early in the developing neural tube and is essential for the maintenance of the multipotent state in NSCs (12) . Additionally, Sox2 is highly expressed in NSCs but not in lineage restricted precursors, such as OPCs (10, 12, 13) . Therefore, an increase in the multipotency of OPCs likely requires Sox2 expression, consistent with the previous observation that sox2-reactivation is essential for the BMP-2-induced conversion of OPCs to NSCs (10) .
Treatment of the P/Sox2-eGFP OPC line (1,000 cells per well in a 384-well plate) with BMP-2 (20 ng/ml; Ϸ20% GFP ϩ ) activated GFP expression in 25-fold more cells than did DMSO (Ͻ1% GFP ϩ ); BMP-2 was therefore used as a reliable and highly reproducible control in the small-molecule screen ( Fig. 1 B and  C) (10) . In-house combinatorial and known drug libraries (Ϸ40,000 compounds at a final assay concentration of 2 M) were then screened to identify molecules that activate Sox2 expression in OPCs (13) . Compounds that activated GFP expression at least 20-fold (Ϸ15% GFP ϩ ) over DMSO control were identified as hits.
Because Sox2 reactivation alone may not be sufficient for OPC reprogramming, a secondary assay was developed to distinguish compounds that simply activate Sox2 from those that expand the differentiation potential of OPCs. OPCs are ordinarily restricted from developing into neuronal lineages in vitro and in vivo; thus differentiation toward the neuronal cell fate would indicate that a compound induces developmental plasticity. Therefore, OPCs were treated with a primary ''hit'' compound for 2 days, expanded in aggregate culture as neuro/oligospheres in bFGFcontaining NSC growth media and then treated under neuronalinducing conditions [NIC; 1 M retinoic acid (RA) and 5 M forskolin] (14) . Under these conditions, untreated OPCs give rise to Ͻ1% neurons, as determined by expression of neuronspecific type III ␤-tubulin (␤III-tubulin).
After filtering out fluorescent compounds that interfere with the screen, nearly 200 compounds were identified that induce Sox2 expression based on GFP fluorescence. These molecules were then examined in the secondary assay, and four compounds were found to have neurogenesis activity including sodium butyrate (NaBu; 50 M), trichostatin A (TSA, 20 nM), MS-275 (500 nM), and Apicidin (500 pM), where the indicated concentrations give rise to the highest percentage of neurons in the secondary assay. Somewhat surprisingly, all of these compounds are HDAC inhibitors and represent members from each of the four major structural classes [short-chain fatty acids (NaBu), hydroxamic acids (TSA), cyclic tetrapeptides (Apicidin), and benzamides (MS-275)]. The fact that all of the hits share a common biological function suggests that inhibition of histone decacetylase (HDAC) activity in OPCs results in epigenetic modifications responsible for the observed developmental plasticity.
Indeed, previous studies with HDAC inhibitors have demonstrated a wide range of activities across a variety of cell lineages, to which neural lineages are no exception. For example, Muller glia can be redirected toward the neuronal lineage via aggregate culture in HDAC inhibitor-supplemented media in vitro, faithfully recapitulating the dedifferentiation process observed in vivo upon retinal injury (15) . Additionally, work done in NSCs has indicated that HDAC inhibitors promote neurogenesis both in vitro and in vivo (14) , and HDAC inhibitors have also been used as chemical tools to demonstrate the necessity of HDAC activity in OPC to OL differentiation (16) and process outgrowth (17) .
As such, it appears that HDAC-mediated gene regulation is important for lineage progression and maintenance in the brain.
Epigenetic Modification of the sox2 Promoter. To test whether HDAC inhibition functions in part through chromatin remodeling, ChIP was used to examine the posttranscriptionally modified state of the histones at the sox2 promoter. A considerable amount of recent evidence has indicated that unique patterns of histone modifications are responsible for transcriptional and lineage control (18) . In particular, methylation of lysine 9 and 27 on histone subunit H3 (H3K9me and H3K27me) are associated with transcriptional repression, whereas methylation of lysine 4 on H3 (H3K4me) is associated with gene activation. More generally, lysine acetylation of histones is also associated with transcriptional activation (19) . Indeed, previous work with morphogen-induced OPC reprogramming indicated that histone and chromatin modifications at the R1 element of the sox2 promoter are central to the plasticity phenotype (10) . Similarly, we observed that the R1 locus of the sox2 promoter exhibited an increase in H3K4me and H3K9Ac and a decrease in H3K9me upon treatment with 20 nM TSA and subsequent expansion in sphere culture (NSC growth media with bFGF; Fig. 2 ). Although the observed histone acetylation is directly modulated by HDAC inhibitor treatment, the changes in methylation likely result from secondary effects (20) . These results indicate that reactivation of sox2 is linked to epigenetic modification at its promoter. In addition, it appears that Sox2 plays a central role during the conversion of OPCs to multipotent NSCs, because siRNAtargeted knockdown of Sox2 dramatically decreased the capacity for neurogenesis in TSA-treated and bFGF-expanded OPCs [Ϸ35% ␤III-tubulin-positive neurons vs. 5%; supporting information (SI) Fig. 4 ]. As such, we suspect that HDAC inhibition results in epigenetic modulation that promotes a more ''open chromatin'' state that is primed for reprogramming. Subsequent expansion in bFGF-supplemented media allows for specification of stem cell identity in the active chromatin state, resulting in complete activation of sox2 and the expansion of developmental potential. Evidence for a stepwise mechanism, driven by chromatin opening and subsequent specification, comes from a mechanistic analysis of the factors involved in the conversion of fibroblasts into embryonic stem cells. In these induced pluripotent cells, c-Myc is responsible for opening the chromatin structure, after which Oct-4 and Sox2 establish the pluripotent state (21). Differentiation Potential. To identify the optimal cell culture parameters required for the induction of developmental plasticity in OPCs, a more thorough analysis was performed. OPCs are a well defined and characterized precursor cell type in the vertebrate CNS (22) , and careful inspection of the OPC cultures before compound treatment confirmed their identity. The OPC cultures exhibited a homogenous bipolar morphology with phase bright cell bodies, consistent with a naive phenotype (Fig. 3A) .
Immunochemical examination confirmed that they expressed the perinatal OPC-specific antigen, A2B5, at Ͼ99% homogeneity (Fig. 3B) . Additionally, the OPCs stained negative for more mature neural markers, including O4, galactocerebroside (GC), myelin basic protein (MBP), glial fibrillary acidic protein (GFAP), ␤III-tubulin, microtubule associate protein 2(aϩb) (Map-2ab), and neurofilament-M (NF-M; data not shown). When OPCs were maintained in growth media in the absence (0.1% DMSO) of TSA for 2 days, expanded in sphere culture for 7 days and then maintained under NIC, astrocyte-inducing conditions (AIC), or OL-inducing conditions (OIC) (14) , they exhibited bipotent differentiation potential, generating OLs (OIC) and astrocytes (AIC) but not neurons (Fig. 3 D-F) . Additionally, when OPCs were treated with TSA (20 nM) for 2 days and then subjected to lineage-specific differentiation conditions directly, they again only exhibited bipotent differentiation potential (data not shown). However, when OPCs were both treated with TSA 20 nM and then expanded in bFGFsupplemented NSC growth media in sphere culture, before lineage specific differentiation, they were capable of giving rise to all three neural lineages ( Fig. 3 G-K) . The expression of neuronal lineage-specific genes was confirmed both immunochemically and via semiquantitative RT-PCR. The OPC-derived neuronal cells expressed Map-2ab, NF-M, Synapsin1, and ␤⌱⌱⌱-tubulin at the protein and mRNA level ( Fig. 3 I 
-L).
Clonal Analysis. We then analyzed TSA-mediated OPC plasticity at the clonal level to rule out the possibility that the neurons observed in these experiments are derived from a residual NSC side population present after isolation of OPCs. Although it appeared that the primary OPC culture did contain a small population of cells with the potential to generate neurons (9 of 366 clones, Ϸ2.5%), OPCs treated with 50 M NaBu (56 of 136 clones, 41%) or 20 nM TSA (41 of 129 clones, 32%) exhibited much higher potential to form neurons than the DMSO-treated control (SI Fig. 5 ). This experiment suggests that the HDAC inhibitor-mediated neuronal potential of OPCs does not result from the amplification of a residual multipotent side population of cells. NaBu was slightly more effective at reprogramming OPCs in this assay. However, NaBu is less specific than TSA and requires a significantly higher concentration (2,500-fold) to inhibit HDAC activity, whereas TSA, on the other hand, is a very potent and specific inhibitor (23) . Therefore, we felt that TSA was a better tool to study HDAC inhibition and, as such, was used in the following analyses.
Microarray Analysis. Genome-wide transcription profiling was then used to further characterize the mechanism of HDAC inhibitor- mediated OPC plasticity and to compare this profile to that which results from BMP-2 induced OPC plasticity. OPCs were treated for 6, 12, 24, and 48 h with TSA (20 nM) or BMP-2 (20 ng/ml), and mRNA transcript profiles were compared with those of untreated cells by using the rat genome (2302) array (Affymetrix, Santa Clara, CA). TSA treatment induced large-scale gene expression changes, displaying a Ͼ2-fold difference in 10,046 of the 30,000 probe sets at, at least, one time point. Of the 10,046 probe sets, 1,233 displayed a consistent pattern across all time points. Comparison of this set with that of the BMP-2-treated cells revealed a very high degree of similarity (SI Fig. 6 ), suggesting that TSA-and BMP-2-induced plasticity converge on a common transcriptional program. The list of 1,233 probe sets was then sorted by function, which identified 145 genes (174 probe sets) involved in development (SI Table 2 ). Analysis of this sublist, with special regard to genes involved in OL differentiation (24) , OPC self-renewal (25, 26) , differentiation of NSCs to OPCs (27) , OPC plasticity (10), or NSC self-renewal (11, 12, 28) , revealed that eight of the most highly down-regulated genes upon treatment with TSA are associated with the differentiation of OPCs to OLs (Table 1) . Interestingly, this group exhibited expression profiles nearly identical to those of BMP-2-treated OPCs and included proteins involved in myelin formation (MBP, MAG, PLP, OMG, and CNPase) (24) as well as other factors that promote the transition of OPCs to OLs (Nkx2.2, Sox10, and Fyn) (24, 29, 30) . The data indicate that the down-regulation of OL-specific gene expression is a common feature of BMP-2-and HDAC-mediated OPC plasticity. More interestingly, 12 of the 145 genes are known to be involved in NSC self-renewal and are significantly upregulated upon treatment with TSA (Table 1 ). This group includes the CNS stem cell markers Nestin and Tenascin C and a variety of transcription factors that mediate neural stem cell identity, including NeuroD1, Foxg1, Id2, Id4, Smad5, Sox9, Hey1, Brca1, Hes1, and Lhx2 (10, (30) (31) (32) (33) . The expression profiles of these 12 genes also exhibit a high degree of similarity in BMP-2-and TSA-treated OPCs. In light of the above experiments, it appears that the two mechanisms of OPC-plasticity may involve similar changes in gene expression patterns during the conversion to a multipotent state.
Discussion
Development and cell fate determination require genetic and epigenetic coordination. For instance, as a naïve cell differentiates toward a particular lineage, modifications of the chromatin occur that activate lineage-specific genes and silence ''stemness'' genes and those associated with alternative cell fates (34) . Although it was thought that this was an irreversible process, recent evidence presented here and elsewhere has refuted that dogma. The most striking example comes from the lab of Shinya Yamanaka (2) , who demonstrated that ectopic expression of Oct-4, Sox2, Klf4 and c-Myc can convert terminally differentiated skin cells into pluripotent embryonic stem cells. Work done in our lab by Chen et al. (5, 35) has also made a significant contribution to this notion, demonstrating that a small molecule, reversine, can expand the differentiation potential of lineage restricted myoblasts to include the osteoblast and adipocyte lineages by modulating the activity of nonmuscle myosin II heavy chain and MEK1. Here, we further demonstrate that global histone acetylation, induced by HDAC inhibition, can partially reverse the lineage restriction of OPCs, thereby inducing developmental plasticity. Indeed, OPCs rapidly acquire several molecular characteristics of NSCs when treated with TSA, including activation of 13 genes that identify or maintain the neural stem cell state while simultaneously silencing a large group of OL lineage-specific genes ( Table 1) .
One of the changes that we suspect is required for OPC plasticity is the reactivation of sox2. Although sox2 is not expressed in OPCs, it is expressed in TSA-treated OPCs and in NSCs, which are thought to give rise to OPCs (7) . Indeed, ChIP analysis showed that the R1 region of the sox2 promoter is modified to a partially open state in response to TSA and fully activated when TSA-treated cells are expanded in bFGF (Fig. 2) . The ChIP data are consistent with the observation that TSAtreated OPCs (demonstrating partial sox2 activation) submitted directly to NIC, without bFGF expansion, do not exhibit mul- tipotent differentiation potential, whereas those that are bFGFexpanded (demonstrating full sox2 activation) are tripotent. Therefore, sox2 expression, driven by the state of the chromatin at its promoter (''partially activated'' vs. ''fully activated'') likely plays a central role in OPC reprogramming. Moreover, inhibition of TSA-induced Sox2 reexpression significantly reduced neurogenesis in TSA-treated OPCs, indicating that Sox2 is a critical component for establishing the multipotent neural stem cell-like state (SI Fig. 4 ). This is consistent with previous work demonstrating that Sox2 activity is required for BMP-2-induced OPC plasticity (10) . There is a heterogeneity in the reprogramming response to TSA treatment (Ϸ35% of cells express Sox2; Fig. 1D ), which was also observed in morphogen-induced plasticity (Ϸ20% of cells are Sox2-positive in response to BMP-2 treatment). This suggests that other factors may be involved, such as stage of the cell cycle, which was shown to play a role in the activity of reversine (35) . The identification of BMP-2 induced genes in HDAC-treated OPCs is in good agreement with previous studies on OPC plasticity. In particular, Smad5 and the Id genes are specific downstream transcriptional regulators of BMP-signaling (33) , and their induction upon HDAC treatment provides strong evidence for cross-talk between these two processes. In addition, Hes1 and Brca1 were previously implicated in BMP-2-induced OPC plasticity, and Brca1, in particular, was found to be associated with the chromatin remodeling complex involved in the reactivation of Sox2 (10) . However, although the expression profiles of BMP-2-and TSA-treated cells look quite similar, and many BMP-signature genes are up-regulated in response to TSA, the BMP pathway is not directly operative in HDAC-mediated OPC plasticity. For instance, BMP-2 expression was not identified in the microarray analysis for TSA-treated or untreated OPCs. Moreover, when TSA-treated OPCs are grown in the presence of Noggin, a BMP antagonist, a robust reprogramming response is still observed (data not shown). Lastly, TSA-treated cells do not express GFAP, and thus HDAC-induced OPC plasticity does not require conversion to type-2 astrocytes, a critical requirement in BMP-induced OPC plasticity (10) .
In summary, we discovered that inhibition of HDAC activity in OPCs acts as a priming event in the induction of developmental plasticity, thereby expanding the differentiation potential to include the neuronal lineage. This conversion was found to be mediated, in part, through reactivation of sox2 and was highly reproducible at the clonal level. Further, genome-wide expression analysis demonstrated that HDAC treatment activated a series of genes that identify or maintain the neural stem cell state while simultaneously silencing a large group of oligodendrocyte lineage-specific genes. Finally, future work will focus on examining the activity of HDAC inhibition in other cell systems and on determining the precise combination of factors that afford OPCs multipotent differentiation potential. Ultimately such studies may lead to small molecules for the study and therapeutic use of stem cell potential.
Materials and Methods
Chemicals. All chemicals were purchased from Sigma (St. Louis, MO), with the exception of Apicidin (Alexis, Lausen, Switzerland). The design of in-house combinatorial small-molecule libraries has been described (13).
Cell Culture. P6 rat optic nerve OPCs were purified to Ͼ98% purity by sequential immunopanning as described (36) and cultured on poly-D-lysine (10 g/ml)-coated flasks in B27-(without vitamin A; Invitrogen, Carlsbad, CA) supplemented DMEM/F12 (Invitrogen) containing PDGF-AA (10 ng/ml; Peprotech, Rocky Hill, NJ) at 37°C with 8% CO 2 . OPCs were used between passage 5 and 20 and were never allowed to reach confluence to maintain the naïve state.
Rat hippocampal NSCs, a generous gift from the laboratory of Fred Gage (The Salk Institute, La Jolla, CA), were cultured on poly-D-lysine (PDL, 10 g/ml) and laminin (10 g/ml; Invitrogen)-coated 75-cm 2 tissue culture flasks in N2 (Invitrogen) supplemented DMEM/F12 containing bFGF (20 ng/ml; Invitrogen).
Transfection, Reporter Assay, and Compound Screens. The P/Sox2-eGFP construct, another generous gift from Fred Gage, was cotransfected with a plasmid conferring neomycin resistance at a 20:1 ratio with FuGENE6 (Roche, Indianapolis, IN), according to the manufacturer's instructions. After 2 days, 400 g/ml G418 (Invitrogen) was added to growth media to generate a stable line. The P/Sox2-eGFP line was then plated at single-cell density on 96-well PDL-coated plates. Individual clones that demonstrated high GFP expression in the presence of BMP-2 (20 ng/ml; Peprotech) and low background fluorescence in the absence of stimulation were then used in high-throughput chemical screens. For screening, P/Sox2-eGFP OPCs were plated at a density of 1,000 cells/well on PDL-coated 384-well plates (Greiner, Philadelphia, PA) in growth media. Compounds were added at a final concentration of 2 M 12 h after plating. Cells were treated with compounds for 2.5 days and fixed for 20 min with a 10% formalin solution, after which cell nuclei were stained with DAPI.
High-Content Imaging. Fixed and stained plates were imaged by using the Opera confocal imaging reader and analyzed with the Opera software (Evotec Technologies, Boston, MA). An air ϫ10 lens was used to capture six images at both wavelengths (460 and 535 nm), representing different locations in a single well. For image analysis, DAPI-stained nuclei and GFP-positive cell bodies were detected by using an algorithm that selects for positive cell bodies and nuclei within a range of fluorescent emission values and sizes (SI Fig. 7) , as determined by fitting parameters to positive (BMP-2, 20 ng/ml) and negative controls (DMSO, 0.1%). Numerical results from the analyzed images were later exported for analysis in Excel (Microsoft, Redmond, WA).
ChIP Assay. ChIP assays using 3 ϫ 10 6 cells per reaction were performed according to the manufacturer's recommendation (catalog no. 17-245; Upstate Biotechnology; Lake Placid, NY). The following antibodies were used for the assay: anti-dimethyl-histone H3-K4 (10 g; Upstate Biotechnology), anti-dimethyl-histone H3-K9 (10 g; Upstate Biotechnology), anti-acetyl-histone H3-K9 (10 g; Upstate Biotechnology), and anti-FLAG (10 g; Sigma). Primer sets for the R1 locus of the sox2 promoter were described (10) . Cycle parameters were 10 sec at 94°C, 20 sec at 60°C, and 90 sec at 72°C for 30 cycles.
Differentiation Conditions and Clonal Analysis. OPCs maintained in growth medium were treated with compound for 2 days, trypsinized (0.05%; Invitrogen), and replated on ultralowadhesion dishes (ULA; Corning, Corning, NY) in NSC growth medium for 7 days to expand the reprogrammed NSLC population. Neurospheres were collected by centrifugation, trypsinized, and plated on PDL and laminin-coated 96-well plates for 2-3 days in NSC growth medium. bFGF was then withdrawn from NSC growth medium, and the NSLC population was directed toward the various neural lineages via medium supplementation with the following factors; oligodendrocyte (OIC); insulin growth factor (IGF1, 500 ng/ml; R & D Systems, Minneapolis, MN) and 100 nM T 3 ; Astrocyte (AIC), leukemia inhibitory factor (LIF, 50 ng/ml; Chemicon, Temecula, CA), and 50 ng/ml BMP-2; Neuron (NIC), 1 M RA and 5 M forskolin. To generate a heterogeneous population of the neural lineages, NSC growth medium was supplemented with 1% FBS and 1 M RA. Differentiation was assessed at 4, 7, and 10 days, depending on the stage-specific presentation of the marker in question.
OPC clones were generated by plating cells at Ϸ1 cell per well
